← Eichor
Study identifier: NCT06769126 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

Condition: Extensive Stage Lung Small Cell Carcinoma · Lung Small Cell Carcinoma, A Subtype · Lung Small Cell Carcinoma, I Subtype  ·  Sponsor: SWOG Cancer Research Network

PhasePhase 2
Planned participants900
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer cells that may give doctors more information about what is driving cancer and how to treat it. Based on the biomarker test results, study doctors can determine the subtype of ES-SCLC that study treatments can target. This study also tests different types of maintenance treatment for ES-SCLC with drugs durvalumab, saruparib, ceralasertib or monalizumab. Maintenance treatment is given after initial treatment and is given to help keep the cancer under control and prevent it from getting worse. Immunotherapy with monoclonal antibodies, such as durvalumab and monalizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Saruparib is a PARP inhibitor. PARP is a protein that helps repair damaged deoxyribonucleic acid (DNA). Blocking PARP may prevent cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for tumor cell growth. Giving biomarker selected personalized maintenance treatment with durvalumab, saruparib, ceralasertib or monalizumab may work better in treating patients with ES-SCLC.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (148)

Loma Linda University Medical CenterLoma Linda, California, United StatesRecruiting
Eisenhower Medical CenterRancho Mirage, California, United StatesRecruiting
University of California Davis Comprehensive Cancer CenterSacramento, California, United StatesRecruiting
UCHealth University of Colorado HospitalAurora, Colorado, United StatesRecruiting
UCHealth Memorial Hospital CentralColorado Springs, Colorado, United StatesRecruiting
Memorial Hospital NorthColorado Springs, Colorado, United StatesRecruiting
Poudre Valley HospitalFort Collins, Colorado, United StatesRecruiting
Cancer Care and Hematology-Fort CollinsFort Collins, Colorado, United StatesRecruiting
Lutheran Hospital - Cancer Centers of ColoradoGolden, Colorado, United StatesRecruiting
UCHealth Greeley HospitalGreeley, Colorado, United StatesRecruiting
Medical Center of the RockiesLoveland, Colorado, United StatesRecruiting
Smilow Cancer Hospital-Derby Care CenterDerby, Connecticut, United StatesRecruiting

+ 136 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06769126